Primary Care Preference Data Could Shape Latent TB Treatment Uptake
People at increased risk for tuberculosis often carry latent tuberculosis infection without symptoms, yet the public health stakes remain substantial. In the United States, elimination efforts depend on identifying these patients early and convincing them to accept treatment in routine primary care, where most prevention work must actually happen. A pilot preference study in BMJ Open examined how people in the USA at increased risk of TB think about treatment for latent infection, using a survey approach designed to inform a future choice-based study.
The clinical relevance is straightforward. LTBI treatment is preventive, not reactive, and its value depends on whether patients view it as acceptable, feasible, and worth the inconvenience of a regimen they may not feel they need. In primary care, where competing demands already crowd the visit, preference data can help clinicians select the attributes of treatment conversations that matter most to patients and can guide the design of more usable prevention strategies.
Survey Design Focused on Real-World Acceptance
This pilot preference study used a detailed survey and achieved a high completion rate. The design also met the pre-specified precision needed to guide the selection of attributes and levels for a future choice-based study, an important methodological step when investigators want to move from general opinion to structured preference measurement. In practical terms, the survey did not simply ask whether participants liked the idea of treatment; it aimed to identify which features should be built into the next stage of research.
Language-concordant community health workers administered the survey, a choice that likely helped reach a broader range of participants across age and education levels within a population with a high prevalence of LTBI. That approach matters in prevention research because latent TB does not cluster neatly in one educational or linguistic subgroup, and uptake questions can be distorted if the survey process itself excludes the people most affected by treatment decisions.
One sentence captures the core implementation challenge: prevention fails when the conversation does not fit the patient in front of the clinician.
Why Preference Research Matters for Latent TB Infection
Treating latent TB infection remains a classic public health paradox. The condition is silent, the benefit is delayed, and the medication burden is immediate. People who feel healthy are being asked to accept a regimen to prevent a future event they may never personally experience, so the decision depends on trust, perceived vulnerability, and how treatment is framed in clinic. A preference study is useful precisely because adherence to LTBI therapy is rarely determined by microbiology alone.
Primary care is the setting where this tension becomes most visible. Patients may encounter treatment recommendations during visits focused on diabetes, hypertension, immigration-related care, or general preventive medicine. The clinician must translate an abstract risk reduction goal into a conversation that is understandable, culturally responsive, and realistic about competing life demands. Survey work that captures preferences across language groups and educational backgrounds helps define which treatment features are most likely to support that conversation.
Methodologic Strengths and the Boundaries of Interpretation
The study’s strongest feature was not a treatment outcome; it was its feasibility signal. A high completion rate suggests the survey format was workable, and the use of pre-specified precision criteria indicates the investigators were planning ahead for a more rigorous preference experiment. In the language of clinical research, that is a meaningful bridge between exploratory work and a future choice-based design that could quantify trade-offs more explicitly.
The administration model also strengthens the study’s operational credibility. Community health workers who are language concordant with participants can reduce comprehension barriers and improve engagement, especially in a topic where medical terminology and preventive framing may otherwise create confusion. For LTBI, communication quality is part of the intervention environment, because preference formation begins the moment the patient understands the problem.
A caution follows directly from the study design. The survey described hypothetical choices and was not built to measure real-world trade-offs. Hypothetical preference does not always predict medication acceptance once patients face side effects, time constraints, pharmacy access problems, or competing priorities. The study also does not represent all non-US-born populations, so any generalization beyond the sampled group should remain restrained.
One result stands out immediately: the survey was feasible, but feasibility does not equal treatment acceptance.
Implications for Preventive TB Care in the USA
Even with those limits, the study has practical value for tuberculosis prevention programs. If future choice-based research can identify the treatment attributes people most value, clinicians may be able to present LTBI options in ways that align better with patient priorities. That could influence not only acceptance, but also persistence with therapy once it begins. In preventive care, the shape of the recommendation can matter as much as the recommendation itself.
The work also points toward a larger structural issue in TB elimination. Broad populations must be treated for LTBI if elimination is to be more than a policy statement, yet the delivery of that prevention still depends on ordinary outpatient encounters. Primary care teams need tools that fit busy clinics, multilingual communities, and patients who do not necessarily arrive thinking of themselves as ill. Preference studies can help identify those tools before they are scaled into practice.
No treatment efficacy data emerge from this pilot, and that is not the point of the paper. Its contribution is earlier in the research chain: it shows that a carefully designed, community-delivered survey can capture meaningful preference information in a high-risk population and can do so with enough precision to justify the next stage of study design. The remaining question is not whether latent TB treatment matters; it is which treatment features patients will actually accept when prevention leaves the page and enters the exam room.